Corpus overview


Overview

MeSH Disease

Transmission

Seroprevalence
    displaying 1 - 10 records in total 122
    records per page




    Long-Term Persistence of Spike Antibody SERO and Predictive Modeling of Antibody SERO Dynamics Following Infection with SARS-CoV-2

    Authors: Louis Grandjean; Anja Saso; Arturo Torres Ortiz; Tanya Lam; James Hatcher; Rosie Thistlethwaite; Mark Harris; Timothy Best; Marina Johnson; Helen Wagstaffe; Elizabeth Ralph; Annabelle Mai; Caroline Colijn; Judith Breuer; Matthew Buckland; Kimberly Gilmour; David Goldblatt; - The Co-Stars Study Team; Huong T Kratochvil; - QCRG Structural Biology Consortium; Anthony Aimon; James M Bennett; Jose Brandao Neto; Aina E Cohen; Alexandre Dias; Alice Douangamath; Louise Dunnett; Oleg Fedorov; Matteo P Ferla; Martin Fuchs; Tyler J Gorrie-Stone; James M Holton; Michael G Johnson; Tobias Krojer; George Meigs; Ailsa J Powell; Johannes Gregor Matthias Rack; Victor L Rangel; Silvia Russi; Rachael E Skyner; Clyde A Smith; Alexei S Soares; Jennifer L Wierman; Kang Zhu; Natalia Jura; Alan Ashworth; John Irwin; Michael C Thompson; Jason E Gestwicki; Frank von Delft; Brian K Shoichet; James S Fraser; Ivan Ahel

    doi:10.1101/2020.11.20.20235697 Date: 2020-11-23 Source: medRxiv

    Background: Antibodies SERO to Severe Acute Respiratory Syndrome Coronavirus-2 MESHD (SARS-CoV-2) have been shown to neutralize the virus in-vitro. Similarly, animal challenge models suggest that neutralizing antibodies SERO isolated from SARS-CoV-2 infected MESHD individuals prevent against disease upon re-exposure to the virus. Understanding the nature and duration of the antibody SERO response following SARS-CoV-2 infection MESHD is therefore critically important. Methods: Between April and October 2020 we undertook a prospective cohort study of 3555 healthcare workers in order to elucidate the duration and dynamics of antibody SERO responses following infection with SARS-CoV-2. After a formal performance SERO evaluation against 169 PCR confirmed cases TRANS and negative controls, the Meso-Scale Discovery assay was used to quantify in parallel, antibody SERO titers to the SARS-CoV-2 nucleoprotein (N), spike (S) protein and the receptor-binding-domain (RBD) of the S-protein. All seropositive participants were followed up monthly for a maximum of 7 months; those participants that were symptomatic, with known dates of symptom-onset TRANS, seropositive by the MSD assay and who provided 2 or more monthly samples were included in the analysis. Survival analysis was used to determine the proportion of sero-reversion (switching from positive to negative) from the raw data. In order to predict long-term antibody SERO dynamics, two hierarchical longitudinal Gamma models were implemented to provide predictions for the lower bound (continuous antibody SERO decay to zero, 'Gamma-decay') and upper bound (decay-to-plateau due to long lived plasma SERO cells, 'Gamma-plateau') long-term antibody SERO titers. Results: A total of 1163 samples were provided from 349 of 3555 recruited participants who were symptomatic, seropositive by the MSD assay, and were followed up with 2 or more monthly samples. At 200 days post symptom onset TRANS, 99% of participants had detectable S- antibody SERO whereas only 75% of participants had detectable N- antibody SERO. Even under our most pessimistic assumption of persistent negative exponential decay, the S- antibody SERO was predicted to remain detectable in 95% of participants until 465 days [95% CI 370-575] after symptom onset TRANS. Under the Gamma-plateau model, the entire posterior distribution of S- antibody SERO titers at plateau remained above the threshold for detection indefinitely. Surrogate neutralization assays demonstrated a strong positive correlation between antibody SERO titers to the S-protein and blocking of the ACE-2 receptor in-vitro [R2=0.72, p<0.001]. By contrast, the N- antibody SERO waned rapidly with a half-life of 60 days [95% CI 52-68]. Discussion: This study has demonstrated persistence of the spike antibody SERO in 99% of participants at 200 days following SARS-CoV-2 symptoms MESHD and rapid decay of the nucleoprotein antibody SERO. Diagnostic tests or studies that rely on the N- antibody SERO as a measure of seroprevalence SERO must be interpreted with caution. Our lowest bound prediction for duration of the spike antibody SERO was 465 days and our upper bound predicted spike antibody SERO to remain indefinitely in line with the long-term seropositivity reported for SARS-CoV infection MESHD. The long-term persistence of the S- antibody SERO, together with the strong positive correlation between the S- antibody SERO and viral surrogate neutralization in-vitro, has important implications for the duration of functional immunity following SARS-CoV-2 infection MESHD.

    Asymptomatic TRANS Employee Screening for SARS-CoV-2: Implementation of and Reactions to an Employer-Based Testing Program.

    Authors: Laura Goetz; Tyler L DeLaughder; Kathleen L Kennedy; Nicholas Schork; Timothy McDaniel; Jeffrey Trent; David Engelthaler; Bishesh Khanal; Martin Smid; Milan Zajicek; Tomas Diviak; Roman Neruda; Petra Vidnerova; Brian Pickering; Andrew D Badley; Rahul Kashyap; AJ Venkatakrishnan; Venky Soundararajan; Jennifer E. Wu; Cécile Alanio; Kurt D'Andrea; Oliva Kuthuru; Jeanette Dougherty; Ajinkya Pattekar; Justin Kim; Nicholas Han; Sokratis A. Apostolidis; Alex C. Huang; Laura Vella; - The UPenn COVID Processing Unit; E. John Wherry; Nuala J. Meyer; Sara Cherry; Paul Bates; Daniel J. Rader; Scott E. Hensley

    doi:10.1101/2020.11.06.20227314 Date: 2020-11-10 Source: medRxiv

    Introduction. Asymptomatic TRANS testing for SARS-CoV-2 among healthcare workers or other essential personnel could remove infected carriers TRANS from the workforce, decreasing chances for transmission TRANS and workplace outbreaks. Results from one-time testing programs have been reported but data regarding longitudinal testing, including information about employees reactions to such programs, is not readily available. Methods. To identify asymptomatic TRANS carriers TRANS of SARS-CoV-2, we implemented a longitudinal screening program for critical on-site employees within our research institute in early April 2020. We conducted a survey of both on-site employees and those working from home in order to measure their reactions to the testing program. Statistical analysis of the survey was conducted with general linear regression and Pearsons Chi-Square tests. Results. Despite an ongoing high community prevalence SERO rate of COVID-19 MESHD, to date only two asymptomatic TRANS employees tested positive out of 1050 tests run during 7 months of the program. However, 12 symptomatic employees not participating in the program have tested positive. The employee survey was completed by 132/306 (43%) employees, with 93% agreeing that asymptomatic TRANS employee screening led to a better and safer working environment and 75% agreeing with on-site public health measures to help contain the virus, but only 58% feeling COVID-19 MESHD was a serious threat to their health. Conclusion. Our results suggest that a longitudinal asymptomatic TRANS employee screening program for SARS-CoV-2 can be accepted by employees and can be used to maintain the health of the workforce, potentially keeping positivity rates below community levels in the face of the ongoing COVID-19 MESHD pandemic.

    COVID-19 MESHD Wastewater Epidemiology: A Model to Estimate Infected Populations

    Authors: Christopher Steven McMahan; Stella Self; Lior Rennert; Corey Kalbaugh; David Kriebel; Duane Graves; Jessica A Deaver; Sudeep Popat; Tanju Karanfil; David L Freedman; Ismail Nabeel; Alexander Charney; Benjamin S Glicksberg; Matthew Levin; David Reich; Dennis Charney; Erwin P Bottinger; Laurie Keefer; Mayte Suarez-Farinas; Girish N Nadkarni; Zahi A Fayad; Claudia De La Cruz; Paola Di Meglio; Paolo Gisondi; Kimme Hyrich; Denis Jullien; Jo Lambert; Hoseah Waweru; Helena Marzo-Ortega; Iain McInnes; Luigi Naldi; Sam Norton; Lluis Puig; Phyllis Spuls; Raj Sengupta; Tiago Torres; RIchard B Warren; John Weinman; Christopher EM Griffiths; Jonathan N Barker; Matthew A Brown; James B Galloway; Catherine H Smith

    doi:10.1101/2020.11.05.20226738 Date: 2020-11-07 Source: medRxiv

    BACKGROUND: Wastewater-based epidemiology (WBE) provides an opportunity for near real-time, cost-effective monitoring of community level transmission TRANS of SARS-CoV-2, the virus that causes COVID-19 MESHD. Detection of SARS-CoV-2 RNA in wastewater can identify the presence of COVID-19 MESHD in the community, but methods are lacking for estimating the numbers of infected individuals based on wastewater RNA concentrations. METHODS: Composite wastewater samples were collected from three sewersheds and tested for SARS-CoV-2 RNA. A Susceptible-Exposed-Infectious-Removed (SEIR) model based on mass rate of SARS-CoV-2 RNA in the wastewater was developed to predict the number of infected individuals. Predictions were compared to confirmed cases TRANS identified by the South Carolina Department of Health and Environmental Control for the same time period and geographic area. RESULTS: Model predictions for the relationship between mass rate of virus release to the sewersheds and numbers of infected individuals were validated based on estimated prevalence SERO from individual testing. A simplified equation to estimate the number of infected individuals fell HP within the 95% confidence limits of the model. The unreported rate for COVID-19 MESHD estimated by the model was approximately 12 times that of confirmed cases TRANS. This aligned well with an independent estimate for the state of South Carolina. CONCLUSIONS: The SEIR model provides a robust method to estimate the total number of infected individuals in a sewershed based on the mass rate of RNA copies released per day. This overcomes some of the limitations associated with individual testing campaigns and thereby provides an additional tool that can be used to better inform policy decisions.

    Prevalence SERO Of COVID-19 MESHD In Rural Versus Urban Areas in a Low-Income Country: Findings from a State-Wide Study in Karnataka, India

    Authors: Manoj Mohanan; Anup Malani; Kaushik Krishnan; Anu Acharya; Brian Hart; Matthew Cross; Keith Stokes; Yung-Chun Chuang; Yu-Wei Cheng; Hung-Yu Sun; Markita P Landry; Sandra Ciesek; Gail Naughton; Martin Latterich; Philip A Mudd; Alfred Spada; Nicole Rindone; Denise Loizou; Lishomwa Ndhlovu; Raavi Gupta; Valerie Tulier-Laiwa; Maya Petersen; Diane V Havlir; - The CLIAHUB Consortium; Joseph DeRisi

    doi:10.1101/2020.11.02.20224782 Date: 2020-11-04 Source: medRxiv

    Although the vast majority of confirmed cases TRANS of COVID-19 MESHD are in low- and middle-income countries, there are relatively few published studies on the epidemiology of SARS-CoV-2 in these countries. The few there are focus on disease prevalence SERO in urban areas. We conducted state-wide surveillance for COVID-19 MESHD, in both rural and urban areas of Karnataka between June 15-August 29, 2020. We tested for both viral RNA and antibodies SERO targeting the receptor binding domain (RBD). Adjusted seroprevalence SERO across Karnataka was 46.7% (95% CI: 43.3-50.0), including 44.1% (95% CI: 40.0-48.2) in rural and 53.8% (95% CI: 48.4-59.2) in urban areas. The proportion of those testing positive on RT-PCR, ranged from 1.5 to 7.7% in rural areas and 4.0 to 10.5% in urban areas, suggesting a rapidly growing epidemic. The relatively high prevalence SERO in rural areas is consistent with the higher level of mobility measured in rural areas, perhaps because of agricultural activity. Overall seroprevalence SERO in the state implies that by August at least 31.5 million residents had been infected by August, nearly an order of magnitude larger than confirmed cases TRANS.

    SARS-CoV-2 Infection MESHD Hospitalization Rate and Infection Fatality Rate among the Non-Congregant Population in Connecticut

    Authors: Shiwani Mahajan; Cesar Caraballo; Shu-Xia Li; Claire Dong; Lian Chen; Sara K Huston; Rajesh Srinivasan; Carrie A Redlich; Albert I Ko; Jeremy S Faust; Howard P Forman; Harlan M Krumholz

    doi:10.1101/2020.10.30.20223461 Date: 2020-11-04 Source: medRxiv

    Importance: COVID-19 MESHD case fatality and hospitalization rates, calculated using the number of confirmed cases TRANS of COVID-19 MESHD, have been described widely in the literature. However, the number of infections confirmed TRANS by testing underestimates the total infections as it is biased based on the availability of testing and because asymptomatic TRANS individuals may remain untested. The infection fatality rate (IFR) and infection hospitalization rate (IHR), calculated using the estimated total infections based on a representative sample of a population, is a better metric to assess the actual toll of the disease. Objective: To determine the IHR and IFR for COVID-19 MESHD using the statewide SARS-CoV-2 seroprevalence SERO estimates for the non-congregate population in Connecticut. Design: Cross-sectional. Setting: Adults TRANS residing in a non-congregate setting in Connecticut between March 1 and June 1, 2020. Participants: Individuals aged TRANS 18 years or above. Exposure: Estimated number of adults TRANS with SARS-CoV-2 antibodies SERO. Main Outcome and Measures: COVID-19 MESHD-related hospitalizations and deaths among adults TRANS residing in a non-congregate setting in Connecticut between March 1 and June 1, 2020. Results: Of the 2.8 million individuals residing in the non-congregate settings in Connecticut through June 2020, 113,515 (90% CI 56,758-170,273) individuals had SARS-CoV-2 antibodies SERO. There were a total of 9425 COVID-19 MESHD-related hospitalizations and 4071 COVID-19 MESHD-related deaths in Connecticut between March 1 and June 1, 2020, of which 7792 hospitalizations and 1079 deaths occurred among the non-congregate population. The overall COVID-19 MESHD IHR and IFR was 6.86% (90% CI, 4.58%-13.72%) and 0.95% (90% CI, 0.63%-1.90%) among the non-congregate population. Older individuals, men, non-Hispanic Black individuals and those belonging to New Haven and Litchfield counties had a higher burden of hospitalization and deaths, compared with younger individuals, women, non-Hispanic White or Hispanic individuals, and those belonging to New London county, respectively. Conclusion and Relevance: Using representative seroprevalence SERO estimates, the overall COVID-19 MESHD IHR and IFR were estimated to be 6.86% and 0.95% among the non-congregate population in Connecticut. Accurate estimation of IHR and IFR among community residents is important to guide public health strategies during an infectious disease outbreak.

    Declining prevalence SERO of antibody SERO positivity to SARS-CoV-2: a community study of 365,000 adults TRANS

    Authors: Helen Ward; Graham Cooke; Christina J Atchison; Matthew Whitaker; Joshua Elliott; Maya Moshe; Jonathan C Brown; Barney Flower; Anna Daunt; Kylie E. C. Ainslie; Deborah Ashby; Christl A. Donnelly; Steven Riley; Ara Darzi; Wendy Barclay; Paul Elliott; Robert Maile; Will Lovell; Shannon Wallet; Natalie M Bowman; Suzanne L Meinig; Matthew C Wolfgang; Saibyasachi N. Choudhury; Mark Novotny; Brian D Aevermann; Richard Scheuermann; Gabrielle Cannon; Carlton Anderson; Julie Marchesan; Mandy Bush; Marcelo Freire; Adam Kimple; Daniel L Herr; Joseph Rabin; Alison Grazioli; Benjamin N. French; Thomas JF Pranzatelli; John A. Chiorini; David E. Kleiner; Stefania Pittaluga; Stephen Hewitt; Peter D. Burbelo; Daniel Chertow; - NIH COVID-19 Autopsy Consortium; - HCA Oral and Craniofacial Biological Network; Karen M Frank; Janice Lee; Richard C. Boucher C. Boucher; Sarah A. Teichmann; Blake M Warner

    doi:10.1101/2020.10.26.20219725 Date: 2020-10-27 Source: medRxiv

    Background The prevalence SERO and persistence of antibodies SERO following a peak SARS-CoV-2 infection MESHD provides insights into its spread in the community, the likelihood of reinfection and potential for some level of population immunity. Methods Prevalence SERO of antibody SERO positivity in England, UK (REACT2) with three cross-sectional surveys between late June and September 2020. 365104 adults TRANS used a self-administered lateral flow immunoassay SERO (LFIA) test for IgG. A laboratory comparison of LFIA results to neutralization activity in panel of sera was performed. Results There were 17,576 positive tests over the three rounds. Antibody SERO prevalence SERO, adjusted for test characteristics and weighted to the adult TRANS population of England, declined from 6.0% [5.8, 6.1], to 4.8% [4.7, 5.0] and 4.4% [4.3, 4.5], a fall HP of 26.5% [-29.0, -23.8] over the three months of the study. There was a decline between rounds 1 and 3 in all age groups TRANS, with the highest prevalence SERO of a positive result and smallest overall decline in positivity in the youngest age group TRANS (18-24 years: -14.9% [-21.6, -8.1]), and lowest prevalence SERO and largest decline in the oldest group (75+ years: -39.0% [-50.8, -27.2]); there was no change in antibody SERO positivity between rounds 1 and 3 in healthcare workers (+3.45% [-5.7, +12.7]). The decline from rounds 1 to 3 was largest in those who did not report a history of COVID-19 MESHD, (-64.0% [-75.6, -52.3]), compared to -22.3% ([-27.0, -17.7]) in those with SARS-CoV-2 infection MESHD infection confirmed TRANS on PCR. Discussion These findings provide evidence of variable waning in antibody SERO positivity over time such that, at the start of the second wave of infection in England, only 4.4% of adults TRANS had detectable IgG antibodies SERO using an LFIA. Antibody SERO positivity was greater in those who reported a positive PCR and lower in older people and those with asymptomatic TRANS infection. These data suggest the possibility of decreasing population immunity and increasing risk of reinfection as detectable antibodies SERO decline in the population.

    Seroprevalence SERO of SARS-CoV-2 IgG antibodies SERO in two regions of Estonia (KoroSero-EST-1)

    Authors: Piia Jogi; Hiie Soeorg; Diana Ingerainen; Mari Soots; Freddy Lattekivi; Paul Naaber; Karolin Toompere; Part Peterson; Liis Haljasmagi; Eva Zusinaite; Hannes Vaas; Merit Pauskar; Arina Shablinskaja; Katrin Kaarna; Heli Paluste; Kai Kisand; Marje Oona; Riina Janno; Irja Lutsar; Raissa Prado Rocha; Alex Fiorini de Carvalho; Pedro Augusto Alves; Jose Luiz Proenca Modena; Artur Torres Cordeiro; Daniela Barreto Barbose Trivella; Rafael Elias Marques; Ronir R Luiz; Paolo Pelosi; Jose Roberto Lapa e Silva

    doi:10.1101/2020.10.21.20216820 Date: 2020-10-23 Source: medRxiv

    Background: In Estonia, during the first wave of COVID-19 MESHD total number of cases confirmed TRANS by PCR was 13.3/10,000, similar in most regions, including capital Tallinn, but in the hotspot of Estonian epidemic, an island Saaremaa, the cumulative incidence was 166.1/10,000. Aim: We aimed to determine the prevalence SERO of SARS-CoV-2 IgG antibodies SERO in these two regions, symptoms associated with infection and factors associated with antibody SERO concentrations. Methods: Participants were selected using stratified (formed by age TRANS decades) random sampling and recruited by general practitioners. IgG were determined from sera by four assays. Symptoms of acute respiratory illness MESHD associated with seropositivity were analyzed by multiple correspondence analysis, antibody SERO concentrations by multiple linear regression. Results: Total of 3608 individual were invited and 1960 recruited From May 8 to July 31, 2020. Seroprevalence SERO was 1.5% (95% confidence interval (CI) 0.9-2.5) and 6.3% (95% CI 5.0-7.9), infection fatality rate 0.1% (95% CI 0.0-0.2) and 1.3% (95% CI 0.4-2.1) in Tallinn and Saaremaa, respectively. Of seropositive subjects 19.2% (14/73) had acute respiratory illness MESHD. Fever HP Fever MESHD, diarrhea HP diarrhea MESHD and the absence of cough HP cough MESHD and runny nose were associated with seropositivity in individuals aged TRANS 50 or more years. IgG concentrations were higher if fever HP fever MESHD, difficulty breathing, shortness of breath MESHD, chest pain HP chest pain MESHD or diarrhea HP diarrhea MESHD was present, or hospitalization required. Conclusion: Similarly to other European countries the seroprevalence SERO of SARS-CoV-2 in Estonia was low even in the hotspot region Saaremaa suggesting that majority of population is still susceptible to SARS-CoV-2. Focusing only on respiratory symptoms may delay accurate diagnosis of SARS-CoV-2 infection MESHD.

    SARS-CoV-2 antibodies SERO in the Southern Region of New Zealand, 2020

    Authors: Alyson Craigie; Reuben McGregor; Alana Whitcombe; Lauren Carlton; David Harte; Michelle Sutherland; Matthew Parry; Erasmus Smit; Gary McAuliffe; James Ussher; Nicole Moreland; Susan Jack; Arlo Upton; Danielle Skinner; Ken Hirata; Sungjun Beck; Aaron F Carlin; Alex E. Clark; Laura Berreta; Daniel Maneval; Felix Frueh; Brett L Hurst; Hong Wang; Klaudia I Kocurek; Frank M Raushel; Jair L. Siqueira-Neto; Thomas D Meek; James H McKerrow

    doi:10.1101/2020.10.20.20215616 Date: 2020-10-23 Source: medRxiv

    Background: During New Zealand's first outbreak in early 2020 the Southern Region had the highest per capita SARS-CoV-2 infection MESHD rate. PCR testing was initially limited by a narrow case definition and limited laboratory capacity, so cases may have been missed. Objectives: To evaluate the Abbott SARS-CoV-2 MESHD IgG nucleocapsid assay, alongside spike-based assays, and to determine the frequency of antibodies SERO among PCR-confirmed and probable cases, contacts, and higher risk individuals in the Southern Region of NZ. Study design: Pre-pandemic sera (n=300) were used to establish assay specificity and sera from PCR-confirmed SARS-CoV-2 patients (n=78) to establish sensitivity SERO. For prevalence SERO analysis, all samples (n=1214) were tested on the Abbott assay, and all PCR- confirmed cases TRANS (n=78), probable cases (n=9), and higher risk individuals with grey-zone (n=14) or positive results (n=11) were tested on four additional SARS-CoV-2 serological assays SERO. Results: The median time from infection onset to serum SERO collection for PCR- confirmed cases TRANS was 14 weeks (range 11-17 weeks). The Abbott assay demonstrated a specificity of 99.7% (95% CI, 98.2%-99.99%) and a sensitivity SERO of 76.9% (95% CI, 66.0%-85.7%). Spike-based assays demonstrated superior sensitivity SERO ranging 89.7-94.9%. Nine previously undiagnosed sero-positive individuals were identified, and all had epidemiological risk factors. Conclusions: Spike-based assays demonstrated higher sensitivity SERO than the Abbott IgG assay, likely due to temporal differences in antibody SERO persistence. No unexpected SARS-CoV-2 infections MESHD were found in the Southern region of NZ, supporting the elimination status of the country at the time this study was conducted.

    PREVALENCE SERO OF ANTIBODIES SERO AGAINST SARS-CoV-2 IN MESHD PROFESSIONALS OF A PUBLIC HEALTH LABORATORY AT SAO PAULO, SP, BRAZIL

    Authors: Valeria Oliveira Silva; Elaine Lopes de Oliveira; Marcia Jorge Castejon; Rosemeire Yamashiro; Cintia Mayumi Ahagon; Giselle Ibette Lopez-Lopes; Edilene Peres Real da Silveira; Marisa Ailin Hong; Maria do Carmo Timenetsky; Carmem aparecida de Freitas Oliveira; Luis Fernando de Macedo Brigido; Satish Lakkakula; Oren Miron; Ehud Rinott; Ricardo Gilead Baibich; Iris Bigler; Matan Malul; Rotem Rishti; Asher Brenner; Yair E. Lewis; Eran Friedler; Yael Gilboa; Sara Sabach; Yuval Alfiya; Uta Cheruti; Nadav Davidovitch; Natalya Bilenko; Jacob Moran-Gilad; Yakir Berchenko; Itay Bar-Or; Ariel Kushmaro; Timothy Spector; Claire J Steves

    doi:10.1101/2020.10.19.20213421 Date: 2020-10-21 Source: medRxiv

    Background: Covid-19 MESHD Serology may document exposure and perhaps protection to the virus, and serological test SERO may help understand epidemic dynamics. To evaluate previous exposure to the virus we estimated the prevalence SERO of antibodies SERO against-SARS-CoV-2 among HPs in Adolfo Lutz Institute, State of Sao Paulo, Brazil. Methods: This study was performed among professionals of Adolfo Lutz Institute in Sao Paulo, Brazil and some administrative areas of the Secretary of Health that shares common areas with the institute. We used a lateral flow immunoassay SERO ( rapid test SERO) to detect IgG and IgM for SARS-CoV-2; positive samples were further evaluated using Roche Electrochemiluminescence assay and SARS-CoV-2 RNA by real time reverse transcriptase polymerase chain reaction (RT-PCR) was also offered to participants. Results: A total of 406 HPs participated. Thirty five (8.6%) tested positive on rapid test SERO and 32 these rapid test SERO seropositive cases were confirmed TRANS by ECLIA.. 43 HPs had SARS-CoV-2 RNA detected at a median of 33 days, and the three cases not reactive at Roche ECLIA had a previous positive RNA. Outsourced professionals (34% seropositive), males TRANS (15%) workers referring COVID-19 MESHD patients at home (22%) and those living farther form the institute tended to have higher prevalence SERO of seropositivity, but in multivariable logistic analysis only outsourced workers and those with COVID patients at home remained independently associated to seropositivity. We observed no relation of seropositivity to COVID samples handling. Presence of at least one symptom was common but some clinical manifestations as anosmia/dysgeusia MESHD anosmia/dysgeusia HP. Fatigue HP, cough MESHD cough HP and fever MESHD fever HP were associated to seropositivity. Conclusions: We documented a relatively high (8.6%) of anti-SARS-CoV-2 serological reactivity in this population, with higher rates among outsourced workers and those with referring cohabitation with COVID-19 MESHD patients. COVID samples handling was not related to increased seropositivity. Some symptoms how strong association to COVID-19 MESHD serology and may be used in scoring tools for screening or diagnosis in resort limited settings.

    Prevalence SERO of antibodies to SARS-CoV-2 SERO in healthy blood SERO donors in New York

    Authors: Kathy Kamath; Elisabeth Baum-Jones; Gregory Jordan; Winston Haynes; Rebecca Waitz; John Shon; Steve Kujawa; Lyn Fitzgibbons; Debra Kessler; Larry L Luchsinger; - Yale IMPACT Team; Patrick Daugherty; Shershah Assadullah; Matthew Leung; Aisling O'Neill; Chhaya Popat; Radhika Kumar; Thomas J Humphries; Rebecca Talbutt; Sarika Raghunath; Philip L Molyneaux; Miriam Schechter; Jeremy Lowe; Andrew Barlow

    doi:10.1101/2020.10.19.20215368 Date: 2020-10-21 Source: medRxiv

    ABSTRACT Despite the high level of morbidity and mortality worldwide, there is increasing evidence for asymptomatic TRANS carriers TRANS of the novel coronavirus SARS-CoV-2. We analyzed blood SERO specimens from 1,559 healthy blood SERO donors, collected in the greater New York metropolitan area between the months of March and July 2020 for antibodies to SARS-CoV-2 SERO virus. Using our proprietary technology, SERA ( Serum SERO Epitope Repertoire Analysis), we observed a significant increase in SARS-CoV-2 seropositivity rates over the four-month period, from 0% [95% CI: 0 - 1.5%] (March) to 11.6% [6.0 - 21.2%] (July). Follow-up ELISA SERO tests using S1 and nucleocapsid viral proteins confirmed most of these results. Our findings are consistent with seroprevalence SERO studies within the region and with reports that SARS-COV-2 infection MESHD SARS-COV-2 infection MESHDs can be asymptomatic TRANS or cause only mild symptoms. IMPORTANCE The COVID-19 MESHD pandemic, caused by the novel coronavirus SARS-CoV-2, has caused vast morbidity and mortality worldwide, yet several studies indicate that there may be a significant number of infected people MESHD who are asymptomatic TRANS or exhibit mild symptoms. In this study, samples were collected from healthy blood SERO donors in a region of rapidly increasing disease burden (New York metropolitan area) and we hypothesized that a subset would be seropositive to SARS-CoV-2. People who experienced mild or no symptoms during SARS-CoV-2 infection MESHD may represent a source for convalescent plasma SERO donors.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.